Description: <p><b>Ivermectin</b> — a semisynthetic avermectin-derived macrocyclic lactone and prescription antiparasitic drug, commonly abbreviated <b>IVM</b> and marketed orally as <b>Stromectol</b>. It is formally an anthelmintic/antiparasitic agent derived from avermectins originally isolated from <i>Streptomyces avermitilis</i>. Its established therapeutic action is activation/modulation of invertebrate glutamate-gated chloride channels, producing paralysis and death of susceptible parasites. In oncology, ivermectin is an investigational drug-repurposing candidate rather than an approved anticancer therapy. Preclinical cancer models report multiple effects including PAK1/AKT/mTOR suppression, mitochondrial dysfunction and oxidative stress, WNT-TCF inhibition, Hippo/YAP1 suppression, chloride-dependent cytotoxicity, and immunogenic cell-death/immune modulation.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>PAK1 degradation with downstream AKT/mTOR suppression and induction of cytostatic/autophagic programs, particularly demonstrated in breast-cancer models.</li>
<li>Mitochondrial dysfunction with ↓ mitochondrial membrane potential, ↓ respiration and ↓ ATP, producing secondary ROS accumulation, oxidative damage and intrinsic apoptosis in several cancer models.</li>
<li>WNT/β-catenin-TCF pathway suppression, reducing WNT-dependent transcription, proliferation, cyclin D1 and cancer-cell growth in responsive models.</li>
<li>Hippo/YAP1 signaling suppression, including ↓ YAP1 expression/nuclear accumulation and ↓ downstream CTGF in susceptible tumor models.</li>
<li>ATP/P2X4/P2X7 signaling modulation and immunogenic cancer-cell death, with increased antitumor T-cell activity and reduced immunosuppressive populations in preclinical breast-cancer models; this provides the rationale for current immune-checkpoint-inhibitor combination trials.</li>
<li>Chloride-channel-associated membrane effects, including chloride-dependent hyperpolarization/cytotoxicity demonstrated in leukemia cells.</li>
<li>Importin α/β-mediated nuclear transport inhibition, potentially affecting transcription factors and other cargo; mechanistically established but tumor relevance varies substantially by model.</li>
<li>JAK/STAT, glycolytic and other metabolic suppression in selected tumor models; these are context-dependent rather than universal ivermectin mechanisms.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral ivermectin is highly lipophilic and poorly water-soluble. After a fasting 12-mg oral dose, reported mean peak plasma concentrations are approximately 31–47 ng/mL at about 4 hours, with a plasma half-life of approximately 18 hours. It is primarily metabolized by CYP3A4 and eliminated predominantly in feces. A high-fat meal can increase systemic bioavailability approximately 2.5-fold. P-glycoprotein-mediated efflux is important in limiting CNS exposure; disruption or inhibition of this protective transport mechanism can increase neurotoxicity risk. Drug interactions and altered hepatic metabolism become particularly important when considering nonstandard high or repeated oncology dosing.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> A major translational limitation is the exposure gap. Standard antiparasitic dosing produces peak circulating concentrations in the tens of ng/mL, corresponding to only roughly 0.04–0.06 µM, whereas many direct anticancer experiments use approximately 2.5–20 µM or higher ivermectin. Thus, common in-vitro anticancer concentrations can exceed conventional human systemic exposure by tens to several hundred-fold. Some tumor-selective or immune-modulatory effects may occur at lower exposures, and oncology trials are testing repeated dosing, but direct extrapolation of micromolar cell-culture cytotoxicity to standard oral dosing is not justified.</p>
<p><b>Clinical evidence status:</b> <b>Approved antiparasitic; oncology investigational.</b> The anticancer evidence remains predominantly preclinical, with substantial cell-culture, organoid, xenograft and immunologic evidence but very limited human efficacy data. A Phase I/II study of ivermectin plus pembrolizumab or balstilimab in metastatic triple-negative breast cancer is recruiting, and a separate randomized Phase II ICONIC study is planned to evaluate ivermectin with standard immune-checkpoint inhibition in solid tumors. No completed large randomized controlled trial has established ivermectin as an effective cancer treatment, and it has no FDA or Health Canada oncology indication.</p>
<h3>Ivermectin Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>PAK1 / AKT / mTOR</td>
<td>PAK1 ↓<br>AKT ↓<br>mTOR ↓<br>Autophagic flux ↑</td>
<td>↔ / not established</td>
<td>Cytostatic autophagy and reduced proliferation</td>
<td>Strong mechanistic evidence in breast-cancer models; ivermectin promotes ubiquitination-mediated degradation of PAK1 with subsequent suppression of AKT/mTOR signaling.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial bioenergetics</td>
<td>Mitochondrial membrane potential ↓<br>Mitochondrial respiration ↓<br>ATP ↓</td>
<td>↔ / ↓ (high exposure)</td>
<td>Bioenergetic failure and apoptosis</td>
<td>Demonstrated particularly in renal, colorectal and esophageal cancer models. Preferential effects over corresponding normal cells have been reported in some models but should not be generalized to all tissues.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial ROS and oxidative damage</td>
<td>ROS ↑ (dose-dependent)</td>
<td>↔ / ↑ (high exposure)</td>
<td>Oxidative stress and intrinsic apoptosis</td>
<td>ROS is principally a downstream consequence of mitochondrial dysfunction rather than a universal primary molecular target. NAC or mitochondrial metabolic rescue can attenuate ivermectin cytotoxicity in several experimental systems.</td>
</tr>
<tr>
<td>4</td>
<td>WNT / β-catenin / TCF</td>
<td>WNT-TCF transcription ↓<br>β-catenin signaling ↓<br>CCND1 ↓</td>
<td>↔ / not established</td>
<td>Reduced proliferation and WNT-dependent tumor growth</td>
<td>Well-characterized preclinical repurposing mechanism, particularly relevant to tumors dependent on canonical WNT-TCF signaling.</td>
</tr>
<tr>
<td>5</td>
<td>Hippo / YAP1 / CTGF</td>
<td>YAP1 ↓<br>YAP1 nuclear localization ↓<br>CTGF ↓ (model-dependent)</td>
<td>↔ / not established</td>
<td>Reduced oncogenic transcription and proliferation</td>
<td>Demonstrated in gastric and other YAP-dependent cancer models. Sensitivity is heterogeneous, and recent organoid work indicates substantial tumor-to-tumor and time-dependent variation.</td>
</tr>
<tr>
<td>6</td>
<td>ATP / P2X4 / P2X7 immune signaling</td>
<td>Immunogenic cell death ↑</td>
<td>Antitumor T-cell activity ↑<br>Immunosuppressive populations ↓ (model-dependent)</td>
<td>Conversion toward an immunologically active tumor microenvironment</td>
<td>Preclinical breast-cancer studies provide the rationale for combining ivermectin with PD-1 pathway inhibition. Human therapeutic benefit remains unproven.</td>
</tr>
<tr>
<td>7</td>
<td>Chloride-dependent membrane signaling</td>
<td>Intracellular Cl⁻ ↑<br>Membrane hyperpolarization ↑<br>Cell death ↑</td>
<td>Lower effect (model-dependent)</td>
<td>Preferential leukemia-cell cytotoxicity</td>
<td>One of the earliest experimentally demonstrated anticancer mechanisms. Evidence is strongest in leukemia and should not be assumed to be dominant in solid tumors.</td>
</tr>
<tr>
<td>8</td>
<td>JAK / STAT signaling</td>
<td>JAK2 ↓<br>p-STAT3 ↓<br>p-STAT5 ↓ (model-dependent)</td>
<td>↔ / not established</td>
<td>Reduced survival and metabolic signaling</td>
<td>Demonstrated in selected models including glioma; not established as a universal ivermectin target across cancer types.</td>
</tr>
<tr>
<td>9</td>
<td>Glycolytic metabolism</td>
<td>GLUT4 ↓<br>HK2 ↓<br>PFK1 ↓<br>Pyruvate ↓<br>ATP ↓ (model-dependent)</td>
<td>↔ / ↓ (high concentration only)</td>
<td>Reduced glycolytic capacity and enhanced metabolic stress</td>
<td>Strongly demonstrated in particular glioma models through GLUT4/JAK/STAT signaling, but insufficient evidence supports treating glycolysis as a universal primary ivermectin mechanism.</td>
</tr>
<tr>
<td>10</td>
<td>Intrinsic apoptosis</td>
<td>Bax ↑<br>Bcl-2 ↓<br>Caspase activity ↑<br>PARP cleavage ↑</td>
<td>↔ / ↑ (high exposure)</td>
<td>Programmed tumor-cell death</td>
<td>Common downstream phenotype following mitochondrial dysfunction, ROS accumulation and signaling disruption.</td>
</tr>
<tr>
<td>11</td>
<td>Importin α / β nuclear transport</td>
<td>Importin-dependent nuclear transport ↓</td>
<td>↓ (exposure-dependent)</td>
<td>Reduced nuclear localization of susceptible cargo</td>
<td>Biochemically important ivermectin activity, but it is not cancer-cell-specific and its contribution to antitumor effects varies by substrate and tumor context.</td>
</tr>
<tr>
<td>12</td>
<td>HIF hypoxia signaling</td>
<td>HIF-1α nuclear localization ↓<br>HIF transcription ↓ (model-dependent)</td>
<td>↓ (context-dependent)</td>
<td>Reduced cellular hypoxia-response transcription</td>
<td>Likely linked partly to importin α/β inhibition. Relevant in hypoxic models but not sufficiently universal to rank as a core ivermectin anticancer mechanism.</td>
</tr>
<tr>
<td>13</td>
<td>Cancer stemness and invasion</td>
<td>Stemness ↓<br>Migration ↓<br>Invasion ↓ (model-dependent)</td>
<td>↔ / not established</td>
<td>Reduced aggressive tumor phenotype</td>
<td>Reported across several preclinical systems and probably reflects convergence of WNT, YAP, AKT and related pathways rather than a single direct target.</td>
</tr>
<tr>
<td>14</td>
<td>NRF2 antioxidant response</td>
<td>↔ / context-dependent</td>
<td>↔ / context-dependent</td>
<td>Not established as a core ivermectin mechanism</td>
<td>Evidence is insufficient to assign a consistent ivermectin-induced NRF2 direction across cancers. It should not currently be presented as a standard ivermectin pathway.</td>
</tr>
<tr>
<td>15</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental exposure often exceeds standard human exposure</td>
<td>Neurotoxicity and systemic toxicity risk ↑ with excessive exposure</td>
<td>Limits translation of direct in-vitro cytotoxicity</td>
<td>Standard oral dosing produces approximately 0.04–0.06 µM peak plasma concentrations, whereas many cancer-cell experiments use several µM. CYP3A4 metabolism, food-dependent exposure, P-glycoprotein-mediated CNS protection, concomitant drugs and repeated high dosing are important clinical constraints. Current oncology studies are investigational and efficacy remains unconfirmed.</td>
</tr>
</table>